Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
Prostate Cancer
About this trial
This is an interventional diagnostic trial for Prostate Cancer
Eligibility Criteria
Inclusion Criteria: Age >= 18 years. Participant or legally authorized representative (LAR) must provide written informed consent before any study-specific procedures or interventions are performed. Patients with suspected BCR of prostate cancer after initial treatment, and a negative or equivocal PSMA PET, regardless of the findings on conventional imaging. Initial treatment may include prostatectomy and/or radiation therapy. PSA of 0.2 ng/mL or higher within 45 days of the scan. Exclusion Criteria: Uncontrolled serious infection. Intercurrent illness or condition that would limit compliance with study requirements. Patients who have undergone any cancer treatment (systemic or radiation therapy) or who have started any supplements or herbal medications intended to treat cancer between the PSMA PET and Axumin PET/CT scans.
Sites / Locations
- Oregon Health & Science UniversityRecruiting
Arms of the Study
Arm 1
Experimental
Fluciclovine PET/CT
Participants will undergo Fluciclovine PET/CT within 30 days of a negative or equivocal PSMA PET scan. After the Fluciclovine PET/CT, the patient will follow up with their treating physician as per standard-of-care. The research team will collect clinical and imaging data at 6 months post Fluciclovine-PET/CT.